1. Biomarkers Definitions Working Group. (2001). Clinical Pharmacology and Therapeutics, 69: 89–95.
2. Knezevic D, Goddard AD, Natraj N, Cherbavaz DB, Clark-Langone KM, Snable J, Watson D, FAlzarano SM, Magi-Galluzzi C, Klein EA, Quale C. (2013). Analytical validation of the Oncotype DX prostate cancer assay—a clinical RT-PCR assay optimized for prostate needle biopsies. BMC Genomics, 14:690
3. Diggans J, Kim SY, Hu Z, Pankratz D, Wong M, Reynolds J, Tom E, Pagan M, Monroe R, Rosai J, Livolsi VA, Lanman RB, Kloos RT, Walsh PS, Kennedy GC. (2015). Machine learning from concept to clinic: reliable detection of BRAF V600E DNA mutations in thyroid nodules using high-dimensional RNA expression data. Pac Symp Biocomputing, 371–82.
4. FDA. Statistical guidance on reporting results from studies evaluating diagnostic tests. 2007. Available from:
http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm071148.htm
.
5. Kloos RT, Reynolds JD, Walsh PS, Wilde JI, Tom EY, Pagan M, Barbacioru C, Chudova DI, Wong M, Friedman L, LiVolsi VA, Rosai J, Lanman RB, Kennedy GC. (2013). Does addition of BRAF V600E mutation testing modify sensitivity or specificity of the Afirma Gene Expression Classifier in cytologically indeterminate thyroid nodules? J Clin Endocrinol Metab, 98:E761–8.